Schoch Steven J 4
4 · Zura Bio Ltd · Filed Jun 22, 2026
Research Summary
AI-generated summary of this filing
Zura Bio Director Steven Schoch Receives 51,000-Share Option Award
What Happened
- Steven J. Schoch, a director of Zura Bio Ltd (ZURA), received a grant/award of a derivative security covering 51,000 shares on June 17, 2026. The reported acquisition price is $0.00 (no cash paid at grant in the filing). This was an award/grant (compensation), not a market purchase or sale.
Key Details
- Transaction date: 2026-06-17. Form 4 filed: 2026-06-22 (filed 5 days after the transaction; Form 4s are typically required within 2 business days).
- Transaction code/type: A = Grant/Award of a derivative security.
- Quantity and price: 51,000 shares; reported price $0.00 (derivative award).
- Shares owned after transaction: Not specified in the provided excerpt—see the full Form 4 for total beneficial ownership.
- Footnote (vesting): The award vests in twelve substantially equal monthly installments over one year beginning June 17, 2026; any remaining unvested portion will vest as of the day before the next annual shareholders’ meeting, subject to continued service.
Context
- This was a compensated equity award (a derivative grant subject to vesting), not an exercise or sale. Such grants are common for directors as service compensation and do not by themselves indicate buying or selling sentiment in the market. Check the full Form 4 for total holdings, exact award type (e.g., options vs. RSUs), and any further terms.
Insider Transaction Report
Form 4
Zura Bio LtdZURA
Schoch Steven J
Director
Transactions
- Award
Share Option (Right to Buy)
[F1]2026-06-17+51,000→ 51,000 totalExercise: $3.62Exp: 2036-06-17→ Class A Ordinary Shares (51,000 underlying)
Footnotes (1)
- [F1]This option vests in twelve substantially equal monthly installments over a one-year period measured from June 17, 2026; provided, that any remaining unvested portion of the option award will vest as of the day immediately preceding the next annual meeting of shareholders following the grant date, subject to the Reporting Person's continued service as of each such vesting date.
Signature
/s/ Kim Davis, Attorney-in-Fact|2026-06-22